US FDA accuses Ranbaxy Laboratories of fraud, concealment and selling substandard drugs
The United States Food and Drug Administration (US FDA) has accused India's largest generics drug maker, Ranbaxy Laboratories, of forging and concealing documents relating to an investigation into the quality of the company's drugs sold in the US market and has filed a motion in the district court of Maryland seeking documents from the Indian firm.
Ranbaxy depends on the US market for 25 percent of its sales and the ongoing investigation is expected to sully its image in the market. Ranbaxy had global sales of $1.61 billion last year, including $386 million in the US.
By Sakshi Ganguli
14 July 2008